Repatha (evolocumab)

pCPA File Number: 20940

Negotiation Status:

Concluded with an LOI

Indication(s):

Primary hyperlipidemia and mixed dyslipidemia

Sponsor/Manufacturer:

Amgen Canada Inc.

CDA-AMC Project Number:

SR0441-000

pCPA Engagement Letter Issued:

2016-08-26

Negotiation Process Concluded:

2017-10-23